Publikationen, an denen er mitarbeitet Jacobo López-Abente Muñoz (2)

2023

  1. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072

2021

  1. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs

    European Respiratory Journal